Items Tagged ‘perjeta’

October 9th, 2014

Impressive Survival Gains with New First-Line Therapy for HER2-Positive Metastatic Breast Cancer


According to recent findings, the combination of targeted agents Herceptin® (trastuzumab) and Perjeta® (perjeta) significantly improves survival for patients with HER2-positive metastatic breast cancer when added to chemotherapy. This data was presented at the 2014 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, September 26–30.[1] HER2 is a protein involved in normal cell […]

View full entry

Tags: Breast Cancer, HER2, herceptin, Metastatic Breast Cancer, News, perjeta, Recurrent Breast Cancer